Circulation:近期心力衰竭住院增加ICD围术期死亡风险

2018-09-18 国际循环编辑部 国际循环

既往研究显示,植入式心律转复除颤器(ICDs)对接受最佳药物治疗、稳定性射血分数减低心力衰竭特定门诊患者安全有效。

既往研究显示,植入式心律转复除颤器(ICDs)对接受最佳药物治疗、稳定性射血分数减低心力衰竭特定门诊患者安全有效。但是,目前不清楚ICD植入前近期因心力衰竭住院是否影响后续结局。

近期,Circulation发表的一项最新研究,对国家血管数据登记处ICD注册研究中射血分数≤35%且植入ICD行一级预防的心力衰竭患者进行事后分析。根据最近一次心力衰竭住院到植入ICD的时间对患者进行分组,采用多因素Logistic回归模型评估ICD植入时间与结局的相关性。

最终对81 180例初次植入ICD行一级预防患者的分析显示,目前,心力衰竭住院者、近期(3个月内)曾因心力衰竭住院者分别为11 563例(14%)和6252例(8%),至少3个月前曾因心力衰竭住院或既往未曾因心力衰竭住院者共计63 365例(78%)。进一步分析显示,目前或近期心力衰竭住院可增加围术期并发症复合终点的发生率(2.60% vs. 1.71% vs. 1.25%,P<0.001)。校正潜在混杂因素后,目前心力衰竭住院患者的死亡、全因再住院风险明显增加;OR值分别为2.25(95%CI:2.02~2.52,P<0.001)和1.89(95%CI:1.79~1.99,P<0.001)。

上述结果提示,对初次植入ICD行一级预防的老年患者而言,与近期未曾因心力衰竭住院相比,目前或近期心力衰竭住院增加围术期并发症及死亡风险。未来,有必要进一步开展前瞻性、真实世界、实用性和有效性比较研究以探讨ICD植入的最佳时机。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1860476, encodeId=829618604e611, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Sun Feb 17 08:42:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985727, encodeId=7c4e1985e27ec, content=<a href='/topic/show?id=bae250886c8' target=_blank style='color:#2F92EE;'>#心力衰竭住院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50886, encryptionId=bae250886c8, topicName=心力衰竭住院)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Nov 10 21:42:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255799, encodeId=54d81255e9934, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Sep 20 11:42:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275415, encodeId=9e5d12e5415a3, content=<a href='/topic/show?id=6a39406551e' target=_blank style='color:#2F92EE;'>#围术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40655, encryptionId=6a39406551e, topicName=围术期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Thu Sep 20 11:42:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345547, encodeId=64a234554ef1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Sep 18 21:22:34 CST 2018, time=2018-09-18, status=1, ipAttribution=)]
    2019-02-17 yilong5287542
  2. [GetPortalCommentsPageByObjectIdResponse(id=1860476, encodeId=829618604e611, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Sun Feb 17 08:42:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985727, encodeId=7c4e1985e27ec, content=<a href='/topic/show?id=bae250886c8' target=_blank style='color:#2F92EE;'>#心力衰竭住院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50886, encryptionId=bae250886c8, topicName=心力衰竭住院)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Nov 10 21:42:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255799, encodeId=54d81255e9934, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Sep 20 11:42:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275415, encodeId=9e5d12e5415a3, content=<a href='/topic/show?id=6a39406551e' target=_blank style='color:#2F92EE;'>#围术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40655, encryptionId=6a39406551e, topicName=围术期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Thu Sep 20 11:42:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345547, encodeId=64a234554ef1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Sep 18 21:22:34 CST 2018, time=2018-09-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1860476, encodeId=829618604e611, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Sun Feb 17 08:42:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985727, encodeId=7c4e1985e27ec, content=<a href='/topic/show?id=bae250886c8' target=_blank style='color:#2F92EE;'>#心力衰竭住院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50886, encryptionId=bae250886c8, topicName=心力衰竭住院)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Nov 10 21:42:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255799, encodeId=54d81255e9934, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Sep 20 11:42:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275415, encodeId=9e5d12e5415a3, content=<a href='/topic/show?id=6a39406551e' target=_blank style='color:#2F92EE;'>#围术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40655, encryptionId=6a39406551e, topicName=围术期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Thu Sep 20 11:42:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345547, encodeId=64a234554ef1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Sep 18 21:22:34 CST 2018, time=2018-09-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1860476, encodeId=829618604e611, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Sun Feb 17 08:42:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985727, encodeId=7c4e1985e27ec, content=<a href='/topic/show?id=bae250886c8' target=_blank style='color:#2F92EE;'>#心力衰竭住院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50886, encryptionId=bae250886c8, topicName=心力衰竭住院)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Nov 10 21:42:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255799, encodeId=54d81255e9934, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Sep 20 11:42:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275415, encodeId=9e5d12e5415a3, content=<a href='/topic/show?id=6a39406551e' target=_blank style='color:#2F92EE;'>#围术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40655, encryptionId=6a39406551e, topicName=围术期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Thu Sep 20 11:42:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345547, encodeId=64a234554ef1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Sep 18 21:22:34 CST 2018, time=2018-09-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1860476, encodeId=829618604e611, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Sun Feb 17 08:42:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985727, encodeId=7c4e1985e27ec, content=<a href='/topic/show?id=bae250886c8' target=_blank style='color:#2F92EE;'>#心力衰竭住院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50886, encryptionId=bae250886c8, topicName=心力衰竭住院)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sat Nov 10 21:42:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255799, encodeId=54d81255e9934, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Sep 20 11:42:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275415, encodeId=9e5d12e5415a3, content=<a href='/topic/show?id=6a39406551e' target=_blank style='color:#2F92EE;'>#围术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40655, encryptionId=6a39406551e, topicName=围术期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Thu Sep 20 11:42:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345547, encodeId=64a234554ef1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Sep 18 21:22:34 CST 2018, time=2018-09-18, status=1, ipAttribution=)]
    2018-09-18 医者仁心5538

    学习了

    0

相关资讯

基于国家专利的中药复方治疗心力衰竭用药规律

通过分析心力衰竭中药复方专利的用药及配伍规律,为中药新药研发提供参考。

JACC Heart Failure:增加体力活动可降低绝经女性心力衰竭风险

既往有关体力活动与心力衰竭(HF)风险的相关性研究结果并不一致。一项有关妇女健康倡议(WHI)的最新分析显示,体力活动(包括步行)与绝经后女性HF发生率呈明显负相关关系。

JAMA Cardiol:右心室功能障碍的心力衰竭患者预后较差

目前,关于普通人群右心室(RV)功能障碍的发病率和预后重要性的数据非常有限。近期,发表于JAMA的一项研究,针对社区老年患者展开队列试验,分析RV功能障碍的发病率及其与心力衰竭(HF)和死亡的关系。

Chest:运动训练和CPAP对心力衰竭和OSA患者的影响

由此可见,在HF和OSA患者中,该研究的初步结果显示单独的运动可以改善OSA,提高生活质量,但CPAP不能。在HF患者OSA的治疗中,该研究是唯一的一项显示任何治疗(运动)可改善所有研究参数的随机试验。该研究的结果突出了运动的重要治疗益处,特别是对于CPAP依从性较低的个体。

PNAS揭示:端粒缩短与心力衰竭有关

端粒(英文名:Telomere)是存在于真核细胞线状染色体末端的一小段DNA-蛋白质复合体,在染色体末端起到保护帽的作用。斯坦福大学医学院的研究人员进行的一项新研究显示,在心肌病患者的心肌细胞中负责收缩的端粒异常短。这一标志性的发现或为研发相关药物开辟了一条新的道路。

JAMA Cardiol:心力衰竭临床试验女性及老年患者入组比例普遍偏低

尽管年龄、性别和种族等差异在临床试验中发挥着重要作用,但关于心力衰竭(HF)研究中的此类人群的入组趋势相关数据非常有限。近期,发表于JAMA杂志一篇综述,对HF研究中老年患者、女性、种族等人群特点进行阐述。